Peer-Reviewed
Publications
As part of our commitment to clinical excellence, we conduct ongoing research and have published several peer-reviewed articles.
Peer-Reviewed
Drug Testing & Evaluation of Drug Use Trends
September 2021: Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database
Saloner B, Whitley P, LaRue L, Dawson E, Huskey A. Polysubstance Use Among Patients Treated with Buprenorphine from a National Urine Drug Test Database. JAMA Netw Open. 2021; 4(8): e2123019. doi:10.1001/jamanetworkopen.2021.23019
December 2020: The Cyclical and Evolving Nature of Methamphetamine Use: An Evaluation of Near Real-Time Urine Drug Test Results
LaRue L, Guevara MG, Whitley P, Dawson E, Twillman RK, Huskey A. The Cyclical and Evolving Nature of Methamphetamine Use: An Evaluation of Near Real-Time Urine Drug Test Results [published online ahead of print December 8, 2020]. J Addict Med. doi: 10.1097/ADM.0000000000000778.
December 2020: Fentanyl Analog Positivity Among Near-Real-Time Urine Drug Test Results in Patients Seeking Health Care
Stanton JD, Whitley P, LaRue L, Bundy WL, Dawson E, Huskey A. Fentanyl Analog Positivity Among Near-Real-Time Urine Drug Test Results in Patients Seeking Health Care. Drug Alcohol Depend. 2020;217:108264. doi: 10.1016/j.drugalcdep.2020.108264.
September 2020: Analysis of Drug Test Results Before and After the US Declaration of a National Emergency Concerning the COVID-19 Outbreak
Wainwright JJ, Mikre M, Whitley P, et al. Analysis of Drug Test Results Before and After the US Declaration of a National Emergency Concerning the COVID-19 Outbreak. JAMA. Published online September 18, 2020. doi:10.1001/jama.2020.17694
January 2020: Evaluation of Trends of Near-Real-Time Urine Drug Test Results for Methamphetamine, Cocaine, Heroin, and Fentanyl
Twillman RK, Dawson E, LaRue L et al. Evaluation of Trends of Near Real-Time Urine Drug Test Results for Cocaine, Methamphetamine, Heroin and Fentanyl. JAMA Netw Open. 2020;3(1):e1918514. doi:10.1001/jamanetworkopen.2019.18514
April 2019: Rate of Fentanyl Positivity Among Urine Drug Test Results Positive for Cocaine or Methamphetamine
LaRue L, Twillman RK, Dawson E., et al. Rate of fentanyl positivity among urine drug test results positive for cocaine or methamphetamine. JAMA Netw Open.2019;2(4):e192851. Doi:10.1001/jamanetworkopen.2019.2851
December 2018: Positivity Rates of Drugs in Patients Treated for Opioid Dependence with Buprenorphine: A comparison of oral fluid and urine using pair collections and LC-MS/MS
West R, Mikel C, Hofilena D, et al. Positivity rates of drugs in patients treated for opioid dependence with buprenorphine: A comparison of oral fluid and urine using paired collections and LC-MS/MS. Drug Alcohol Depend. 2018; 193:183-191.
June 2017: Detection of Naltrexone and Naltrexol in Urine of Patients Prescribed Embeda®
West R, Guevara M, Mikel C. Detection of naltrexone and naltrexol in patients prescribed Embeda®. J Opioid Manag. May/June 2017; 13(3): 139-40.
February 2017: Detection of Hydrocodone and Morphine as Metabolites in Oral Fluid by LC-MS/MS in Patients Prescribed Codeine
West RE, Guevara MG, Mikel C, et al. Detection of hydrocodone and morphine as metabolites in oral fluid by LC-MS/MS in patients prescribed codeine. Ther Drug Monit. 2017 Feb; 39(1): 88-90.
December 2016: Drug Monitoring Impacts Substance-use Treatment Planning and Patient Outcomes
Rzetelny A, Zeller B, Miller N, et al. Definitive LC-MS/MS Drug Monitoring Impacts Substance-use Treatment Planning and Patient Outcomes: A Brief Report. J Addict Med. 2016;10(6):443-447.
July 2015: Counselors’ Clinical Use of Definitive Drug Testing Results in Their Work with Substance-Use Clients
Rzetelny A, Zeller B, Miller N, et al. Counselors’ Clinical Use of Definitive Drug Testing Results in Their Work with Substance-Use Clients: a Qualitative Study. Int J Ment Health Addict. 2016;14:64-80.
Pharmacogenetics
September 2020: Genetic Testing for BCHE Variants Identifies Patients at Risk of Prolonged Neuromuscular Blockade in Response to Succinylcholine
Zhu GD, Dawson E, Huskey A, Gordon RJ, Del Tredici AL. Genetic Testing for BCHE Variants Identifies Patients at Risk of Prolonged Neuromuscular Blockade in Response to Succinylcholine. Pharmgenomics Pers Med. 2020;13:405-414. doi: 10.2147/PGPM.S263741.
May 2020: Recommendations for Clinical Warfarin Genotyping Allele Selection
Pratt VM, Cavallari LH, Del Tredici AL, et al. Recommendations for Clinical Warfarin Sensitivity Genotyping Allele Selection: A Report of the Association for Molecular Pathology and the College of American Pathologists [published online ahead of print, 2020 May 4]. J Mol Diagn. 2020;S1525-1578(20)30298-1.
September 2019: Ambiguous Pharmacogenetic Test Results in a Patient with a Bone Marrow Transplant
Espin FE, Dedek M, Moreno TA, et al. Ambiguous pharmacogenetic genotyping results in a patient with bone marrow transplantation. Journal of Laboratory Medicine. 2019; 43(5): 283-286
May 2019: Recommendations for Clinical CYP2C9 Genotyping Allele Selection
Pratt VM, Cavallari LH, Del Tredici AL, et al. Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2019;21(5):746-755
March 2019: Development of a Screening Test for HLA-B*15:02
Fang H, Xu X, Kaur K, et al. A Screening Test for HLA-B∗15:02 in a Large United States Patient Cohort Identifies Broader Risk of Carbamazepine-Induced Adverse Events. Front Pharmacol. 2019;10:149
May 2018: Recommendations for Clinical CYP2C19 Genotyping Allele Selection
Pratt VM, Del Tredici AL, Hachad H, et al. Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology. J Mol Diagn. 2018;20(3):269-276
April 2018: CYP2D6 Allele Frequencies in the United States
Del Tredici AL, Malhotra A, Dedek M, et al. Frequency of CYP2D6 Alleles Including Structural Variants in the United States. Front Pharmacol. 2018;9:305
March 2014: Exploring Rates of Abnormal Pharmacogenetic Findings in a Pain Management Practice
Kirsh KL, Ehlenberger E, Huskey A, et al. Exploring rates of abnormal pharmacogenetic findings in a pain practice. J Pain Palliat Care Pharmacother. 2014;28(1):28-32
Patent: HLA-B*15:02 Single Nucleotide Polymorphism
Moreno, T., Fang, H., Xu, X., Dedek, M. and Kaur, K., inventors. Single Nucleotide Polymorphism In HLA-B*15:02 And Use Thereof. US patent 10,683,548. June 16, 2020.
Moreno, T., Fang, H., Xu, X., Dedek, M. and Kaur, K., inventors. Single Nucleotide Polymorphism In HLA-B*15:02 And Use Thereof. World patent WO2017004189A1. January 5, 2017.
Contact Us
Patient Billing
(877) 451-7337
Monday-Friday 6:00AM-4:00PM PT
Corporate Headquarters
(877) 451-3534
